Omega Announces Third Quarter 2018 Financial Results

Nov 05, 2018 06:00 am
HUNT VALLEY, Md. -- 

Omega Healthcare Investors, Inc. (NYSE:OHI) (the “Company” or “Omega”) today announced its results of operations for the three-month period ended September 30, 2018. The Company reported for the three-month period ended September 30, 2018 net income of $59.1 million or $0.28 per common share. The Company also reported Funds From Operations (“FFO”) for the quarter of $159.4 million or $0.76 per common share, Adjusted Funds From Operations (“AFFO” or “Adjusted FFO”) of $162.6 million or $0.77 per common share, and Funds Available For Distribution (“FAD”) of $144.0 million.

FFO for the third quarter of 2018 includes $4.0 million of non-cash stock-based compensation expense, $1.2 million of unrealized loss on warrants and $2.0 million in recovery of provisions for uncollectible accounts (Adjusted FFO excludes those three items). FFO, AFFO and FAD are non-GAAP financial measures. For more information regarding these non-GAAP measures, see the “Funds From Operations” schedule.

GAAP NET INCOME

For the three-month period ended September 30, 2018, the Company reported net income of $59.1 million, or $0.28 per common share, on operating revenues of $221.9 million. This compares to a net loss of ($137.5) million, or ($0.67) per common share, on operating revenues of $219.6 million, for the same period in 2017.

For the nine-month period ended September 30, 2018, the Company reported net income of $229.0 million, or $1.10 per common share, on operating revenues of $661.9 million. This compares to net income of $39.8 million, or $0.19 per common share, on operating revenues of $687.2 million, for the same period in 2017.

The year-to-date increase in net income compared to the prior year was primarily due to $233.6 million of impairments on direct financing leases and real estate recorded in 2017 versus $26.7 million recorded in 2018, $22.0 million in decreased interest refinancing costs, a $7.3 million decrease in provision for uncollectible accounts and $1.8 million in increased gains on the sale of assets. The increase in net income was partially offset by a $32.3 million reduction in revenue associated with the Orianna Health Systems (“Orianna” and f/k/a ARK) portfolio, a favorable $10.4 million contractual settlement recorded in the first quarter of 2017, a $9.6 million increase in general and administrative expenses and $3.3 million in increased interest expense.

CEO COMMENTS

Taylor Pickett, Omega’s Chief Executive Officer, stated, “I am happy with the continued progress we made this quarter. We were able to successfully transition 22 of our legacy Orianna facilities to current operators with good rent coverage. We continue to make headway with the sale and/or transition of the remaining legacy Orianna facilities and we expect this process to conclude in the next few months. Furthermore, we remain confident that the final resolution will result in our previously stated range of $32 million to $38 million of annual rent or rent equivalents from the assets that previously constituted our Orianna portfolio.” Mr. Pickett concluded, “We have substantially completed our strategic disposition program and, during the quarter, we began the process of redeploying the capital realized from this program. While the pipeline is currently not as robust as we would hope, we believe we will continue to find opportunities to allocate capital to quality assets run by sophisticated operators. As such, in the coming 12 months we would envision returning to our historical growth model where acquisitions meaningfully exceed dispositions.”

2018 RECENT DEVELOPMENTS AND THIRD QUARTER HIGHLIGHTS

In Q4 2018, the Company

  • declared a $0.66 per share quarterly common stock dividend.

In Q3 2018, the Company

  • transitioned 22 Orianna facilities for annual contractual rent of $17 million.
  • sold 7 assets for consideration of $26 million in cash and a $5 million seller note.
  • completed $131 million in new investments.
  • invested $44 million in capital renovation and construction-in-progress projects.
  • paid a $0.66 per share quarterly common stock dividend.

In Q2 2018, the Company

  • sold 47 assets for consideration of $138 million in cash, a $25 million seller note and $53 million in buyer assumed debt.
  • completed $77 million in new investments.
  • invested $54 million in capital renovation and construction-in-progress projects.
  • paid a $0.66 per share quarterly common stock dividend.

In Q1 2018, the Company

  • sold 14 facilities and had 3 mortgage loans repaid, totaling $98 million in net cash proceeds.
  • invested $38 million in capital renovation and construction-in-progress projects.
  • completed $30 million in new investments.
  • increased its quarterly common stock dividend rate to $0.66 per share.

THIRD QUARTER 2018 RESULTS

Operating Revenues and Expenses – Operating revenues for the three-month period ended September 30, 2018 totaled $221.9 million, which included $17.9 million of non-cash revenue.

Operating expenses for the three-month period ended September 30, 2018 totaled $105.8 million and consisted of $70.7 million of depreciation and amortization expense, $22.9 million of impairment on real estate properties, $10.3 million of general and administrative expense, $4.0 million of stock-based compensation expense and a $2.0 million recovery of uncollectible accounts. For more information on impairment charges, see the Asset Impairments and Dispositions section below.

Other Income and Expense – Other income and expense for the three-month period ended September 30, 2018 was a net expense of $51.2 million, primarily consisting of $47.8 million of interest expense, $2.2 million of amortized deferred financing costs and $1.2 million in unrealized loss on warrants, in Interest income and other – net.

Funds From Operations – For the three-month period ended September 30, 2018, FFO was $159.4 million, or $0.76 per common share, on 210 million weighted-average common shares outstanding, compared to a loss of ($46.8) million, or a loss of ($0.24) per common share on 207 million weighted-average common shares outstanding, for the same period in 2017.

The $159.4 million of FFO for the three-month period ended September 30, 2018 includes the impact of $4.0 million of non-cash stock-based compensation expense, $2.0 million in recovery for uncollectible accounts and $1.2 million in unrealized loss on warrants.

The ($46.8) million loss of FFO for the three-month period ended September 30, 2017 includes the impact of $194.7 million in impairment on direct financing leases, $11.9 million in provision for uncollectible accounts and $3.9 million of non-cash stock-based compensation expense.

Adjusted FFO was $162.6 million, or $0.77 per common share, for the three-month period ended September 30, 2018, compared to $163.6 million, or $0.79 per common share, for the same period in 2017. For further information see the “Funds From Operations” schedule.

FINANCING ACTIVITIES

Equity Shelf Program and Dividend Reinvestment and Common Stock Purchase Plan – During the three-month period ended September 30, 2018, the Company sold 0.3 million shares of its common stock, generating $9.9 million of gross proceeds. The following table outlines shares of the Company’s common stock issued under its Equity Shelf Program and its Dividend Reinvestment and Common Stock Purchase Plan in 2018:

 

 

Equity Shelf (At-the-Market) Program for 2018

(in thousands, except price per share)
       

Q1

 

 

Q2

 

Q3

  Year To Date
Number of shares

 

912

 

912
Average price per share

$

 

$

30.93

 

$

$ 30.93
Gross proceeds

$

 

$

28,218

 

$

$ 28,218
 

Dividend Reinvestment and Common Stock Purchase Plan

for 2018

(in thousands, except price per share)
 
Q1     Q2   Q3   Year To Date
Number of shares 189 759 309 1,257
Average price per share $ 25.87 $ 29.22 $ 31.82 $ 29.36
Gross proceeds $ 4,886 $ 22,164 $ 9,854 $ 36,904
 

2018 THIRD QUARTER PORTFOLIO ACTIVITY

$175 Million of New Investments in Q3 2018 – In Q3 2018, the Company completed approximately $131 million of new investments and $44 million in capital renovations and new construction consisting of the following:

$131 Million Loan – On September 28, 2018, the Company entered into a $131.3 million secured term loan with an unrelated third party. The loan is secured by a collateral assignment of mortgages covering seven skilled nursing facilities (“SNFs”), three independent living facilities (“ILFs”), and one assisted living facility (“ALF”) located in Pennsylvania and Virginia. The loan bears an interest rate of 9.35% and matures on February 28, 2019. On or before maturity, the Company expects to obtain fee simple title to the facilities and add the facilities to an existing operator’s master lease.

$44 Million Capital Renovation Projects – In addition to the new investment outlined above, in Q3 2018, the Company invested $43.6 million under its capital renovation and construction-in-progress programs.

Orianna – During the quarter, the Company transitioned 22 of the legacy Orianna facilities to five existing Omega operators with combined annual contractual rents of $16.8 million.

On October 12, 2018 the Company sold a legacy Orianna facility to a third party operator for consideration of $4.0 million.

The sale and/or transition of the remaining 19 legacy Orianna facilities is progressing under the supervision of the Bankruptcy Court and we expect this process to conclude in the next few months. The timing of the process and our receipt of the sales proceeds is subject to the approval of the Bankruptcy Court.

ASSET IMPAIRMENTS AND DISPOSITIONS

During the third quarter of 2018, the Company sold seven assets (one previously classified as assets held for sale and one classified as a direct financing lease) for consideration consisting of $25.9 million in cash and a $5.1 million seller note, recognizing a loss of approximately $5.4 million. The Company recorded impairment charges of $22.9 million primarily related to reducing the net book values on eight facilities to their estimated fair values or expected selling prices.

As of September 30, 2018, the Company had 10 facilities classified as assets held for sale totaling $17.8 million. The Company expects to sell these facilities over the next few quarters.

As part of its strategic asset repositioning program, in addition to the $17.8 million of assets held for sale, the Company is evaluating an additional $60+ million of potential disposition opportunities within its portfolio and may incur additional impairments or potential losses on the dispositions.

DIVIDENDS

On October 16, 2018, the Board of Directors declared a common stock dividend of $0.66 per share, to be paid November 15, 2018 to common stockholders of record as of the close of business on October 31, 2018.

2018 ADJUSTED FFO GUIDANCE AFFIRMED

The Company affirmed of its 2018 Adjusted FFO guidance range of $3.03 to $3.06 per diluted share.

Bob Stephenson, Omega’s CFO commented, “Our financial performance improved sequentially in the third quarter as we transitioned some of our legacy Orianna facilities to current operators and began to redeploy capital from our strategic disposition program. We believe resolution of the remaining legacy Orianna portfolio and further capital investment will continue to improve operating performance, enhancing our dividend coverage and returning us to our targeted leverage range, to which we remain committed.” Mr. Stephenson continued, “With a well-laddered debt profile and no near-term maturities, we believe we are well-positioned from a balance sheet perspective to weather the interest rate volatility and continue to grow our business.”

The following table presents a reconciliation of Omega’s guidance regarding Adjusted FFO to projected GAAP earnings.

 

2018 Annual Adjusted FFO
Guidance Range
(per diluted common share)

Full Year
Net Income $ 1.48 - $1.51
Depreciation 1.35
Gain on assets sold – net

(0.05)

Real estate impairment   0.13
FFO $ 2.91 - $2.94
Adjustments:
Unrealized gain on warrants -
Purchase option buyout 0.01
Provision for uncollectible accounts 0.03
Stock-based compensation expense   0.08
Adjusted FFO $ 3.03 - $3.06

Note: All per share numbers rounded to 2 decimals.

The Company's Adjusted FFO guidance for 2018 reflects the impact of capital renovation projects, $345 million of assets sold and mortgages repaid to us through Q3 2018, the sale of $18 million of assets held for sale, approximately $60+ million of potential divestitures and the redeployment of capital from asset sales. It assumes the Company will not be recording revenue related to its Orianna restructure/sale portfolio in the fourth quarter of 2018. The Company expects to record approximately $4.2 million in revenue in Q4 related to the Orianna transition portfolio (in Q3 2018, Omega transitioned 22 facilities subject to direct financing leases with a net carrying value of approximately $184.5 million from Orianna to other operators with annual contractual rent of approximately $16.8 million). It also excludes the impact of gains and losses from the sale of assets, certain revenue and expense items, interest refinancing expense, capital transactions, acquisition costs, and additional provisions for uncollectible accounts, if any. The Company may, from time to time, update its publicly announced Adjusted FFO guidance, but it is not obligated to do so.

The Company's guidance is based on a number of assumptions, which are subject to change and many of which are outside the Company’s control. If actual results vary from these assumptions, the Company's expectations may change. Without limiting the generality of the foregoing, the timing and completion of acquisitions, divestitures, capital and financing transactions, and variations in stock-based compensation expense may cause actual results to vary materially from our current expectations. There can be no assurance that the Company will achieve its projected results.

CONFERENCE CALL

The Company will be conducting a conference call on Monday, November 5, 2018 at 10 a.m. Eastern to review the Company’s 2018 third quarter results and current developments. Analysts and investors within the United States interested in participating are invited to call (877) 511-2891. The Canadian toll-free dial-in number is (855) 669-9657. All other international participants can use the dial-in number (412) 902-4140. Ask the operator to be connected to the “Omega Healthcare’s Third Quarter 2018 Earnings Call.”

To listen to the conference call via webcast, log on to www.omegahealthcare.com and click the “earnings call” icon on the Company’s home page. Webcast replays of the call will be available on the Company’s website for two weeks following the call.

Omega is a real estate investment trust that invests in the long-term healthcare industry, primarily in skilled nursing and assisted living facilities. Its portfolio of assets is operated by a diverse group of healthcare companies, predominantly in a triple-net lease structure. The assets span all regions within the US, as well as in the UK.

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding Omega’s or its tenants’, operators’, borrowers’ or managers’ expected future financial condition, results of operations, cash flows, funds from operations, dividends and dividend plans, financing opportunities and plans, capital markets transactions, business strategy, budgets, projected costs, operating metrics, capital expenditures, competitive positions, acquisitions, investment opportunities, dispositions, facility transitions, growth opportunities, expected lease income, continued qualification as a REIT, plans and objectives of management for future operations and statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will” and other similar expressions are forward-looking statements. These forward-looking statements are inherently uncertain, and actual results may differ from Omega’s expectations. Omega does not undertake a duty to update these forward-looking statements, which speak only as of the date on which they are made.

Omega’s actual results may differ materially from those reflected in such forward-looking statements as a result of a variety of factors, including, among other things: (i) uncertainties relating to the business operations of the operators of Omega’s properties, including those relating to reimbursement by third-party payors, regulatory matters and occupancy levels; (ii) regulatory and other changes in the healthcare sector; (iii) changes in the financial position of Omega’s operators; (iv) the ability of any of Omega’s operators in bankruptcy to reject unexpired lease obligations, modify the terms of Omega’s mortgages and impede the ability of Omega to collect unpaid rent or interest during the pendency of a bankruptcy proceeding and retain security deposits for the debtor's obligations, and other costs and uncertainties associated with operator bankruptcies; (v) the availability and cost of capital; (vi) changes in Omega’s credit ratings and the ratings of its debt securities; (vii) competition in the financing of healthcare facilities; (viii) Omega’s ability to maintain its status as a REIT; (ix) Omega’s ability to sell assets held for sale or complete potential asset sales on a timely basis and on terms that allow Omega to realize the carrying value of these assets; (x) Omega’s ability to re-lease, otherwise transition or sell underperforming assets on a timely basis and on terms that allow Omega to realize the carrying value of these assets; (xi) the effect of economic and market conditions generally, and particularly in the healthcare industry; (xii) the potential impact of changes in the SNF and assisted living facility (“ALF”) market or local real estate conditions on the Company’s ability to dispose of assets held for sale for the anticipated proceeds or on a timely basis, or to redeploy the proceeds therefrom on favorable terms; (xiii) changes in interest rates; (xiv) changes in tax laws and regulations affecting REITs; and (xv) other factors identified in Omega’s filings with the Securities and Exchange Commission. Statements regarding future events and developments and Omega’s future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward looking statements. Omega undertakes no obligation to update any forward-looking statements contained in this announcement.

 

OMEGA HEALTHCARE INVESTORS, INC.

CONSOLIDATED BALANCE SHEETS

(in thousands, except per share amounts)

 
September 30,   December 31,
2018     2017
(Unaudited)
ASSETS
Real estate properties
Real estate investments $ 7,700,636 $ 7,655,960
Less accumulated depreciation   (1,515,846 )   (1,376,828 )
Real estate investments – net 6,184,790 6,279,132
Investments in direct financing leases – net 163,467 364,965
Mortgage notes receivable – net   708,178       671,232  
7,056,435 7,315,329
Other investments – net 511,668 276,342
Investment in unconsolidated joint venture 32,159 36,516
Assets held for sale – net   17,826       86,699  
Total investments 7,618,088 7,714,886
 
Cash and cash equivalents 9,768 85,937
Restricted cash 1,371 10,871
Accounts receivable – net 336,825 279,334
Goodwill 644,201 644,690
Other assets   31,711       37,587  
Total assets $ 8,641,964     $ 8,773,305  
 
LIABILITIES AND EQUITY
Revolving line of credit $ 360,000 $ 290,000
Term loans – net 900,847 904,670
Secured borrowings – net 53,098
Senior notes and other unsecured borrowings – net 3,327,393 3,324,390
Accrued expenses and other liabilities 253,560 295,142
Deferred income taxes   14,198       17,747  
Total liabilities   4,855,998       4,885,047  
 
Equity:

Common stock $.10 par value authorized – 350,000 shares, issued
and outstanding – 200,693 shares as of September 30, 2018
and 198,309 as of December 31, 2017

 

20,069

 

19,831

Common stock – additional paid-in capital 5,012,544 4,936,302
Cumulative net earnings 2,068,295 1,839,356
Cumulative dividends paid (3,606,181

)

(3,210,248 )
Accumulated other comprehensive loss   (32,382 )     (30,150 )
Total stockholders’ equity 3,462,345 3,555,091
Noncontrolling interest   323,621       333,167  
Total equity   3,785,966       3,888,258  
Total liabilities and equity $ 8,641,964     $ 8,773,305  
 
 
OMEGA HEALTHCARE INVESTORS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
Unaudited

(in thousands, except per share amounts)

   
Three Months Ended Nine Months Ended
September 30, September 30,
2018   2017   2018   2017
Revenue    
Rental income $ 192,276 $ 194,063 $ 579,075 $ 580,597
Income from direct financing leases 264 614 1,374 31,722
Mortgage interest income 18,396 16,920 51,809 49,173
Other investment income 10,259 7,245 27,883 21,437
Miscellaneous income   657     796     1,791     4,250  
Total operating revenues 221,852 219,638 661,932 687,179
 
Expenses
Depreciation and amortization 70,711 71,925 210,681 212,268
General and administrative 10,278 7,688 33,845 24,275
Stock-based compensation 3,962 3,872 12,107 11,350
Acquisition costs - - - (22 )
Impairment on real estate properties 22,868 17,837 26,685 35,610
Impairment on direct financing leases - 194,659 15 197,968
(Recovery) provision for uncollectible accounts   (2,000 )   11,899     6,363     13,667  
Total operating expenses 105,819 307,880 289,696 495,116
 
Income (loss) before other income and expense 116,033 (88,242 ) 372,236 192,063
Other income (expense)
Interest income and other – net (1,214 ) 4 496 262
Interest expense (47,764 ) (47,383 ) (143,857 ) (140,509 )
Interest – amortization of deferred financing costs (2,238 ) (2,228 ) (6,723 ) (7,273 )
Interest – refinancing costs - - - (21,965 )
Contractual settlement - - - 10,412
Realized gain on foreign exchange   27     95     20     235  
Total other expense (51,189 ) (49,512 ) (150,064 ) (158,838 )
 
Income (loss) before (loss) gain on assets sold 64,844 (137,754 ) 222,172 33,225
(Loss) gain on assets sold – net   (5,361 )   693     9,248     7,491  
Income (loss) from continuing operations 59,483 (137,061 ) 231,420 40,716
Income tax expense (804 )

 

(999 ) (2,185 ) (2,690 )
Income (loss) from unconsolidated joint venture   383  

 

  545     (254 )   1,728  
Net income (loss) 59,062 (137,515 ) 228,981 39,754
Net (income) loss attributable to noncontrolling interest   (2,456 )   5,837     (9,619 )   (1,735 )
Net income (loss) available to common stockholders $ 56,606   $ (131,678 ) $ 219,362   $ 38,019  
 

Income per common share available to common
stockholders:

Basic:
Net income (loss) available to common stockholders $ 0.28   $ (0.67 ) $ 1.10   $ 0.19  
Diluted:
Net income (loss) $ 0.28   $ (0.67 ) $ 1.10   $ 0.19  
 
Dividends declared per common share $ 0.66   $ 0.64   $ 1.98   $ 1.89  
 
Weighted-average shares outstanding, basic   200,910     197,890     199,773     197,445  
Weighted-average shares outstanding, diluted   210,437     206,662     208,905     206,502  
 
   
OMEGA HEALTHCARE INVESTORS, INC.
FUNDS FROM OPERATIONS
Unaudited

(in thousands, except per share amounts)

Three Months Ended

Nine Months Ended

September 30, September 30,
2018   2017   2018   2017
   
Net income (loss) $ 59,062 $ (137,515 ) $ 228,981 $ 39,754
Add back loss (deduct gain) from real estate dispositions 5,361 (693 ) (9,248 ) (7,491 )

Add back loss from real estate dispositions of
unconsolidated joint venture

  30         670        
Sub-total 64,453 (138,208 ) 220,403 32,263
Elimination of non-cash items included in net income:
Depreciation and amortization 70,711 71,925 210,681 212,268
Depreciation - unconsolidated joint venture 1,381 1,657 4,504 4,973

Add back non-cash provision for impairments on real
estate properties

22,868 17,837 26,685 35,610

Add back non-cash provision for impairments on real
estate properties of unconsolidated joint venture

          608        
Funds from operations (“FFO”) $ 159,413   $ (46,789 ) $ 462,881     $ 285,114  
 
Weighted-average common shares outstanding, basic 200,910 197,890 199,773 197,445
Restricted stock and PRSUs 812 382 271
Omega OP Units   8,715     8,772     8,750       8,786  
Weighted-average common shares outstanding, diluted   210,437     206,662     208,905       206,502  
 
Funds from operations available per share $ 0.76   $ (0.24 ) $ 2.22     $ 1.38  
 
Adjustments to calculate adjusted funds from operations:
Funds from operations $ 159,413 $ (46,789 ) $ 462,881 $ 285,114
Deduct one-time revenue (1,881 )
Add back (deduct) unrealized loss (gain) on warrants 1,231 (371 )
Deduct contractual settlement (10,412 )
Deduct acquisition costs (22 )
Add back one-time buy-out of purchase option 2,000
Add back impairment for direct financing leases 194,659 15 197,968

(Deduct) add back (recovery) provision for uncollectible
accounts

(2,000 ) 11,899 6,363 13,667
Add back interest refinancing expense 23,539
Add back non-cash stock-based compensation expense   3,962     3,872     12,107       11,350  
Adjusted funds from operations (“AFFO”) $ 162,606   $ 163,641   $ 482,995     $ 519,323  
 
Adjustments to calculate funds available for distribution:
Non-cash interest expense $ 2,212 $ 2,200 $ 6,643 $ 7,861
Capitalized interest (2,898 )

 

(1,972 ) (7,802 ) (5,867 )
Non-cash revenues   (17,897 )

 

  (13,314 )   (53,709 )     (49,399 )
 
Funds available for distribution (“FAD”) $ 144,023   $ 150,555   $ 428,127     $ 471,918  
 

Funds From Operations (“FFO”), Adjusted FFO and Funds Available for Distribution (“FAD”) are non-GAAP financial measures. For purposes of the Securities and Exchange Commission’s Regulation G, a non-GAAP financial measure is a numerical measure of a company’s historical or future financial performance, financial position or cash flows that exclude amounts, or is subject to adjustments that have the effect of excluding amounts, that are included in the most directly comparable financial measure calculated and presented in accordance with GAAP in the income statement, balance sheet or statement of cash flows (or equivalent statements) of the company, or include amounts, or is subject to adjustments that have the effect of including amounts, that are excluded from the most directly comparable financial measure so calculated and presented. As used in this press release, GAAP refers to generally accepted accounting principles in the United States of America. Pursuant to the requirements of Regulation G, the Company has provided reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures.

The Company calculates and reports FFO in accordance with the definition and interpretive guidelines issued by the National Association of Real Estate Investment Trusts (“NAREIT”), and consequently, FFO is defined as net income (computed in accordance with GAAP), adjusted for the effects of asset dispositions and certain non-cash items, primarily depreciation and amortization and impairments on real estate assets, and after adjustments for unconsolidated partnerships and joint ventures. Adjustments for unconsolidated partnerships and joint ventures will be calculated to reflect funds from operations on the same basis. The Company believes that FFO, Adjusted FFO and FAD are important supplemental measures of its operating performance. Because the historical cost accounting convention used for real estate assets requires depreciation (except on land), such accounting presentation implies that the value of real estate assets diminishes predictably over time, while real estate values instead have historically risen or fallen with market conditions. The term FFO was designed by the real estate industry to address this issue. FFO described herein is not necessarily comparable to FFO of other real estate investment trusts, or REITs, that do not use the same definition or implementation guidelines or interpret the standards differently from the Company.

Adjusted FFO is calculated as FFO excluding the impact of non-cash stock-based compensation and certain revenue and expense items identified above. FAD is calculated as Adjusted FFO less non-cash interest expense and non-cash revenue, such as straight-line rent. The Company believes these measures provide an enhanced measure of the operating performance of the Company’s core portfolio as a REIT. The Company’s computation of Adjusted FFO and FAD are not comparable to the NAREIT definition of FFO or to similar measures reported by other REITs, but the Company believes that they are appropriate measures for this Company.

The Company uses these non-GAAP measures among the criteria to measure the operating performance of its business. The Company also uses Adjusted FFO among the performance metrics for performance-based compensation of officers. The Company further believes that by excluding the effect of depreciation, amortization, impairments on real estate assets and gains or losses from sales of real estate, all of which are based on historical costs and which may be of limited relevance in evaluating current performance, FFO can facilitate comparisons of operating performance between periods and between other REITs. The Company offers these measures to assist the users of its financial statements in analyzing its operating performance and not as measures of liquidity or cash flow. These non-GAAP measures are not measures of financial performance under GAAP and should not be considered as measures of liquidity, alternatives to net income or indicators of any other performance measure determined in accordance with GAAP. Investors and potential investors in the Company’s securities should not rely on these non-GAAP measures as substitutes for any GAAP measure, including net income.

The following tables present selected portfolio information, including operator and geographic concentrations, and lease and loan maturities for the period ended September 30, 2018:

   
As of September 30, 2018

As of September 30, 2018

Balance Sheet Data

Total # of
Properties

 

Total
Investment
($000’s)

 

% of
Investment

# of
Operating
Properties (1)

 

# of
Operating
Beds (1)

Real Estate Investments 851   $ 7,700,636   90 % 846   84,759
Direct Financing Leases 18 163,467 2 % 18 1,753
Mortgage Notes Receivable 53     708,178   8 % 53   5,764
922 $ 8,572,281 100 % 917 92,276
Assets Held For Sale 10     17,826
Total Investments 932 $ 8,590,107
 
           
Investment Data

Total # of
Properties

 

Total
Investment
($000’s)

 

% of
Investment

# of
Operating
Properties(1)

 

# of
Operating
Beds (1)

 

Investment
per Bed
($000’s)

Skilled Nursing
Facilities/Transitional Care

795

$

7,083,109

83

%

793

84,520

$

84

Senior Housing (2) 127     1,489,172   17 % 124   7,756 $ 192
922 $ 8,572,281 100 % 917 92,276 $ 93
Assets Held For Sale 10     17,826
Total Investments 932 $ 8,590,107

(1) Excludes facilities which are non-operating, closed and/or not currently providing patient services.

(2) Includes ALFs, memory care and independent living facilities.

 
     
Revenue Composition ($000's)
         
Revenue by Investment Type Three Months Ended Nine Months Ended
September 30, 2018   September 30, 2018
Rental Property $ 192,276 87 % $ 579,075   88 %
Direct Financing Leases 264 0 % 1,374 0 %
Mortgage Notes 18,396 8 % 51,809 8 %
Other Investment Income and Miscellaneous Income - net   10,916   5 %     29,674   4 %
$ 221,852 100 % $ 661,932 100 %
 
   
Revenue by Facility Type Three Months Ended Nine Months Ended
September 30, 2018   September 30, 2018
Skilled Nursing Facilities/Transitional Care $ 183,691   83 % $ 548,210   83 %
Senior Housing 27,245 12 % 84,048 13 %
Other   10,916   5 %     29,674   4 %
$ 221,852 100 % $ 661,932 100 %
 
     

Rent/Interest Concentration by Operator
($000’s)

 

# of
Properties (1)

 

Total

Annualized
Contractual
Rent/Interest (1)(2)

 

% of Total

Annualized
Contractual
Rent/Interest

Ciena Healthcare 74 $ 94,277 11.9 %
CommuniCare Health Services, Inc. 46 61,624 7.8 %
Genesis Healthcare 50 57,327 7.2 %
Signature Holdings II, LLC 58 50,556 6.4 %
Saber Health Group 45 43,379 5.5 %
Health & Hospital Corporation 44 35,469 4.5 %
Maplewood Real Estate Holdings, LLC 14 31,367 4.0 %
Guardian LTC Management Inc. 32 31,192 3.9 %
Daybreak Venture, LLC. 57 30,017 3.8 %
Diversicare Healthcare Services 35 28,959 3.7 %
Remaining Operators (3) 427     328,167   41.3 %
882 $ 792,334 100.0 %
 

(1) Excludes facilities which are non-operating, closed and/or not currently providing patient services.

(2) 3Q 2018 contractual rent/interest annualized; includes mezzanine and term loan interest.

(3) Excludes 20 Orianna facilities, 14 Preferred Care facilities and one Safe Haven facility due to their bankruptcy status: all
      facilities of these three operators are expected to be transitioned or sold.

 
     

Geographic Concentration by
Investment ($000’s)

Total # of
Properties (1)

 

Total

Investment (1)

 

% of Total
Investment

Texas 116 $ 825,921 9.7 %
Florida 93 822,624 9.6 %
Michigan 53 686,212 8.0 %
Ohio 60 629,884 7.3 %
Indiana 65 582,802 6.8 %
California 54 497,588 5.8 %
Pennsylvania 43 464,270 5.4 %
Tennessee 35 284,102 3.3 %
Virginia 18 280,718 3.3 %
North Carolina 32 274,264 3.2 %
Remaining 31 states (2) 298     2,821,299   32.9 %
867 8,169,684 95.3 %
United Kingdom 55     402,597   4.7 %
922 $ 8,572,281 100.0 %

(1) Excludes 10 properties with total investment of $17.8 million classified as assets held for sale.

(2) Includes New York City 2nd Avenue development project.

 
 

Rent and Loan Maturities
($000's)

As of September 30, 2018

Operating Lease Expirations

& Loan Maturities

Year  

2018 Lease
Rent

  2018 Interest  

2018 Lease
and Interest
Rent

  %
2018 $ - $ - $ - 0.0 %
2019 734 1,442 2,176 0.3 %
2020 5,397 3,444 8,841 1.1 %
2021 6,241 140 6,381 0.8 %
2022 37,336 - 37,336 4.7 %
2023 19,047 - 19,047 2.4 %
 
Notes: Based on annualized 3rd quarter 2018 contractual rent and interest.
Excludes Safe Haven contractual revenue of approximately $1.4 million expiring in 2019 due to its bankruptcy status.

Orianna revenue of approximately $26.1 million does not contractually expire until 2026 or later and therefore is also excluded due
to their bankruptcy status.

 

The following tables present operator revenue mix, census and coverage data based on information provided by our operators as of June 30, 2018:

 
Operator Revenue Mix (1) As of June 30, 2018

Medicaid

 

Medicare /
Insurance

 

Private / Other

   
Three-months ended June 30, 2018 52.7 % 34.8 % 12.5 %
Three-months ended March 31, 2018 51.3 % 36.4 % 12.3 %
Three-months ended December 31, 2017 52.9 % 34.6 % 12.5 %
Three-months ended September 30, 2017 52.9 % 34.7 % 12.4 %
Three-months ended June 30, 2017 51.9 % 35.9 % 12.2 %
 
(1) Excludes all facilities considered non-core.
 
   
Operator Census and Coverage (1)     Coverage Data
Occupancy (2)  

Before

Management
Fees

 

After

Management
Fees

 
Twelve-months ended June 30, 2018 82.5 % 1.70x 1.34x
Twelve-months ended March 31, 2018 82.4 % 1.69x 1.33x
Twelve-months ended December 31, 2017 82.3 % 1.71x 1.34x
Twelve-months ended September 30, 2017 82.2 % 1.72x 1.35x
Twelve-months ended June 30, 2017 82.4 % 1.71x 1.34x
 
(1) Excludes all facilities considered non-core.
(2) Based on available (operating) beds.
 

The following table presents a debt maturity schedule as of September 30, 2018:

   

Debt Maturities
($000’s)

Unsecured Debt

Year

Line of Credit and
Term Loans (1)

 

Senior
Notes/Other (2)

 

Sub Notes (3)

 

Total Debt
Maturities

2018 $ -   $ -   $ - $ -
2019 - - - -
2020 - - - -
2021 360,000 - 20,000 380,000
2022 905,410 - - 905,410
2023 - 700,000 - 700,000
Thereafter   -     2,650,000     -     2,650,000
$ 1,265,410   $ 3,350,000   $ 20,000   $ 4,635,410
 
(1)   The $360 million Line of Credit borrowings excludes $4.4 million net deferred financing costs and can be extended into 2022. The $905 million is comprised of a: $425 million US Dollar term loan, £100 million term loan (equivalent to $130 million in US dollars), $100 million term loan to Omega’s operating partnership and $250 million term loan (excludes $4.6 million net deferred financing costs related to the term loans).
(2) Excludes net discounts and deferred financing costs.
(3) Excludes $0.3 million of fair market valuation adjustments.
 

The following table presents investment activity for the three and nine month periods ended September 30, 2018:

   
Investment Activity ($000's) Three Months Ended Nine Months Ended
September 30, 2018   September 30, 2018
Funding by Investment Type $ Amount   %     $ Amount   %  
Real Property $ -   0.0 % $ 52,497   14.0 %
Construction-in-Progress 32,443 18.5 % 90,671 24.3 %
Capital Expenditures 11,206 6.4 % 45,035 12.1 %
Investment in Direct Financing Leases - 0.0 % 15 0.0 %
Mortgages - 0.0 % 44,200 11.8 %
Other   131,300   75.1 %     141,300   37.8 %
Total $ 174,949 100.0 % $ 373,718 100.0 %
 

For Omega Healthcare Investors, Inc.
Matthew Gourmand
SVP, Investor Relations
or
Bob Stephenson, 410-427-1700
CFO